CO2019001044A2 - Composición de cannabis - Google Patents

Composición de cannabis

Info

Publication number
CO2019001044A2
CO2019001044A2 CONC2019/0001044A CO2019001044A CO2019001044A2 CO 2019001044 A2 CO2019001044 A2 CO 2019001044A2 CO 2019001044 A CO2019001044 A CO 2019001044A CO 2019001044 A2 CO2019001044 A2 CO 2019001044A2
Authority
CO
Colombia
Prior art keywords
treating
relates
sleep disorder
cannabis composition
cannabis extract
Prior art date
Application number
CONC2019/0001044A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019001044(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CO2019001044A2 publication Critical patent/CO2019001044A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un método para tratar un trastorno del sueño. Preferentemente, la invención se refiere a un método para tratar un trastorno del sueño que comprende la etapa de administrar una composición farmacéutica que comprende un extracto de Cannabis y opcionalmente uno o más portadores, diluyentes, adyuvantes, excipientes farmacéuticamente aceptables o cualquier combinación de estos, el extracto de Cannabis que comprende una fracción de terpeno que comprende limoneno en una cantidad de al menos aproximadamente 5.4 % en peso de la fracción de terpeno
CONC2019/0001044A 2016-08-03 2019-02-01 Composición de cannabis CO2019001044A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
CO2019001044A2 true CO2019001044A2 (es) 2019-04-30

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0001044A CO2019001044A2 (es) 2016-08-03 2019-02-01 Composición de cannabis

Country Status (15)

Country Link
US (2) US11779562B2 (es)
EP (1) EP3493798A4 (es)
JP (1) JP2019523283A (es)
KR (2) KR20210013645A (es)
CN (1) CN109843287A (es)
AU (4) AU2017307643B2 (es)
BR (1) BR112019001852A2 (es)
CA (1) CA3031810A1 (es)
CL (1) CL2019000270A1 (es)
CO (1) CO2019001044A2 (es)
IL (2) IL264461B2 (es)
MX (1) MX2019001285A (es)
PE (1) PE20200726A1 (es)
SG (1) SG11201900665VA (es)
WO (1) WO2018023163A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900501RA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018183115A1 (en) * 2017-03-30 2018-10-04 Ojai Energetics Pbc Methods and compositions for enhancing health
AU2018100837B4 (en) * 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
WO2019241804A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400320B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
EP2844243B8 (en) 2012-05-03 2019-12-18 Echo Pharmaceuticals B.V. Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP4137142A1 (en) 2013-03-14 2023-02-22 Purple Mundo, Inc. Bioactive concentrates and uses thereof
MX2015013202A (es) * 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
ES2739292T3 (es) * 2013-10-29 2020-01-30 Biotech Inst Llc Cultivo, producción, procesamiento y uso de cannabis de especialidad
EP3062774A2 (en) 2013-10-31 2016-09-07 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CA2952934A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
CA2996626A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
MX2017005277A (es) * 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
EA201791299A1 (ru) 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
MX2017009846A (es) 2015-01-31 2018-04-11 Constance Therapeutics Inc Metodos para la preparacion de extractos y composiciones de aceite de cannabis.
CA2977802A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
JP2019523282A (ja) 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
SG11201900501RA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
AU2021240297B2 (en) 2023-08-24
AU2019253841A1 (en) 2019-11-14
IL296008A (en) 2022-10-01
IL264461B1 (en) 2024-05-01
EP3493798A1 (en) 2019-06-12
IL264461B2 (en) 2024-09-01
SG11201900665VA (en) 2019-02-27
EP3493798A4 (en) 2020-05-06
KR20210013645A (ko) 2021-02-04
IL264461A (en) 2019-02-28
US20230414559A1 (en) 2023-12-28
AU2021240297A1 (en) 2021-10-28
AU2019253841B2 (en) 2021-07-01
KR20190035791A (ko) 2019-04-03
AU2018100923C4 (en) 2019-10-31
BR112019001852A2 (pt) 2019-05-07
JP2019523283A (ja) 2019-08-22
PE20200726A1 (es) 2020-07-21
US11779562B2 (en) 2023-10-10
AU2018100923A4 (en) 2018-08-09
CN109843287A (zh) 2019-06-04
AU2017307643B2 (en) 2019-07-25
CA3031810A1 (en) 2018-02-08
AU2017307643A1 (en) 2018-07-05
AU2018100923B4 (en) 2018-09-27
IL296008B2 (en) 2024-09-01
WO2018023163A1 (en) 2018-02-08
MX2019001285A (es) 2019-06-13
IL296008B1 (en) 2024-05-01
CL2019000270A1 (es) 2019-10-04
US20220347155A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CO2019001044A2 (es) Composición de cannabis
PE20230607A1 (es) Composicion de cannabis
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
CL2019000268A1 (es) Composición de cannabis.
CO2017013231A2 (es) Composiciones que comprenden una cepa bacteriana del género parabacteroides
CO2017013287A2 (es) Composiciones que comprenden una cepa bacteriana del género roseburia
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
PE20171138A1 (es) Modulacion inmunitaria
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CO2020000328A2 (es) Formulaciones a largo plazo
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MD4763B1 (ro) Compoziţie farmaceutică
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
NI202000017A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
AR108792A1 (es) Composiciones que comprenden timolol
AR104200A1 (es) Carboximetilcisteina para tratamiento tópico de estrías
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.